Log in

Relevant bibliographies by topics / Non-small cell lung cancer / Journal articles

To see the other types of publications on this topic, follow the link: Non-small cell lung cancer.

Journal articles on the topic 'Non-small cell lung cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Non-small cell lung cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cheng, Wenhan, M. D, MS c, et al. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer." International Journal of Medical Reviews and Case Reports 4, Reports in Clinical Medicine and (2020): 1. http://dx.doi.org/10.5455/ijmrcr.atezolizumab-non-small-cell-lung-cancer.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Skenduli, Ilir, and Perlat Kapisyzi. "Surgery for Non Small Cell Lung Cancer - A Systematic Review." International Journal of Science and Research (IJSR) 11, no. 5 (2022): 1551–56. http://dx.doi.org/10.21275/sr22518021202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kammaev, K. A. "Non-small cell lung carcinoma. Clinical case." Filin’s Clinical endoscopy 66, no. 3 (2024): 62–65. http://dx.doi.org/10.31146/2415-7813-endo-66-3-62-65.

Full text

Abstract:

In 2020, 2.2 million new cases of lung cancer were reported. The main form of lung cancer is non-small cell carcinoma (85%). Non-small cell lung cancer has 3 subtypes: adenocarcinoma, large cell and squamous cell carcinoma. Squamous cell lung cancer occurs in 20-40% of all lung cancers. Squamous cell lung cancer is associated with an unfavorable outcome. 5-year survival rate not exceeding 18%.

APA, Harvard, Vancouver, ISO, and other styles

6

_, _. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (2008): 228. http://dx.doi.org/10.6004/jnccn.2008.0021.

Full text

Abstract:

Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States

APA, Harvard, Vancouver, ISO, and other styles

7

Skřičková, Jana, Bohdan Kadlec, and Ondřej Venclíček. "Non-small cell lung cancer." Vnitřní lékařství 63, no. 11 (2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ettinger, David S., Wallace Akerley, Gerold Bepler, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 8, no. 7 (2010): 740–801. http://dx.doi.org/10.6004/jnccn.2010.0056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ettinger, David S., Wallace Akerley, Hossein Borghaei, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 10, no. 10 (2012): 1236–71. http://dx.doi.org/10.6004/jnccn.2012.0130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fromer, Margot J. "Non-Small-Cell Lung Cancer." Oncology Times 30, no. 4 (2008): 21–25. http://dx.doi.org/10.1097/01.cot.0000313049.69678.f6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hill, A., P. Fisher, and D. Yeomanson. "Non-small cell lung cancer." BMJ 345, sep27 1 (2012): e6443-e6443. http://dx.doi.org/10.1136/bmj.e6443.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cox, James D. "Non-small Cell Lung Cancer." Chest 89, no. 4 (1986): 284S—288S. http://dx.doi.org/10.1378/chest.89.4_supplement.284s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Pearson, F. Griffith. "Non-small Cell Lung Cancer." Chest 116 (December 1999): 500S—503S. http://dx.doi.org/10.1378/chest.116.suppl_3.500s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Held-Warmkessel, Jeanne, and Linda Schiech. "Non-small cell lung cancer." Nursing 44, no. 2 (2014): 32–42. http://dx.doi.org/10.1097/01.nurse.0000441877.57254.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Non-small cell lung cancer." Nursing 44, no. 2 (2014): 42–43. http://dx.doi.org/10.1097/01.nurse.0000441878.64877.76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Haskell, Charles M., and E. Carmack Holmes. "Non-small cell lung cancer." Current Problems in Cancer 11, no. 1 (1987): 1–52. http://dx.doi.org/10.1016/s0147-0272(87)80002-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Dediu, M., and W. Hilbe. "Non-small cell lung cancer." memo - Magazine of European Medical Oncology 1, no. 4 (2008): 247–51. http://dx.doi.org/10.1007/s12254-008-0068-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Haskell, Charles M., and E. Carmack Holmes. "Non-small cell lung cancer." Disease-a-Month 34, no. 2 (1988): 55–108. http://dx.doi.org/10.1016/0011-5029(88)90024-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Goldstraw, Peter, David Ball, James R. Jett, et al. "Non-small-cell lung cancer." Lancet 378, no. 9804 (2011): 1727–40. http://dx.doi.org/10.1016/s0140-6736(10)62101-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Frei, Emil. "Non-small Cell Lung Cancer." Chest 112, no. 4 (1997): 266S—268S. http://dx.doi.org/10.1378/chest.112.4_supplement.266s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Vokes, Everett E., and Jacob D. Bitran. "Non-Small-Cell Lung Cancer." Chest 106, no. 3 (1994): 659–61. http://dx.doi.org/10.1378/chest.106.3.659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sause, William T. "Non-small cell lung cancer." International Journal of Radiation Oncology*Biology*Physics 42, no. 1 (1998): 110. http://dx.doi.org/10.1016/s0360-3016(98)80061-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kurata, Takayasu, Isamu Okamoto, Kenji Tamura, and Masahiro Fukuoka. "Amrubicin for non-small-cell lung cancer and small-cell lung cancer." Investigational New Drugs 25, no. 5 (2007): 499–504. http://dx.doi.org/10.1007/s10637-007-9069-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer." Journal of the Japanese Association for Chest Surgery 3, no. 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Beattie, Edward J., and Noel M. Raskin. "Progress in lung cancer: Non-oat cell (non-small cell lung cancer)." Japanese Journal of Surgery 17, no. 5 (1987): 313–22. http://dx.doi.org/10.1007/bf02470629.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pearson, F. Griffith. "The role of adjuvant therapy in completely resected, non-small cell lung cancer." Journal of the Japanese Association for Chest Surgery 19, no. 3 (2005): 272–73. http://dx.doi.org/10.2995/jacsurg.19.272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Conda, Ashith, and Pranav Chadha. "Stereotactic Body Radiation Therapy for Early - Stage, Inoperable Non-Small Cell Lung Cancer." International Journal of Science and Research (IJSR) 10, no. 1 (2021): 1187–90. https://doi.org/10.21275/sr21120160058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Laera, Letizia, and Silvia Novello. "Immunotherapy and non-small cell lung cancers." Cancer Breaking News 5, no. 3 (2017): 6–10. http://dx.doi.org/10.19156/cbn.2017.0052.

Full text

Abstract:

Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

29

Kalkan, Fatih, and Mehmet Özler. "DELTA-9 TETRAHYDROCANNABINOID AND GEMSITABIN COMBINATION ON NON-SMALL CELL (SQUAMOUS CELL, SK-MES-1) LUNG CANCER CELL LINE." Era's Journal of Medical Research 10, no. 01 (2023): 1–12. http://dx.doi.org/10.24041/ejmr2023.1.

Full text

Abstract:

Squamous cell carcinoma falls within the category of non-small cell lung cancers, presenting a considerable challenge in terms of treatment management. There has been growing interest in the potential anti-cancer properties of Delta-9 tetrahydrocannabinol. Gemcitabine, a nucleoside analog, has shown effectiveness against diverse cancer types. This study aimed to assess the combined efficacy of Delta-9 tetrahydrocannabinol and Gemcitabine in treating cancer. The squamous lung cancer cell line required for our study was provided by the stem cell unit. The doses were determined as 5µm/L and 10µm/

APA, Harvard, Vancouver, ISO, and other styles

30

Bhargav, Manjunath Hegde, Ganapati Hegde Mahesh, Channappagol Chetan, and P. Dayananda. "Review on Deep Learning Technique for Detecting Non-Small Cell Lung Cancer." Journal of Information Technology and Sciences 5, no. 3 (2019): 15–20. https://doi.org/10.5281/zenodo.3377126.

Full text

Abstract:

<em>The lung cancer is one of the major cancers in the world. Almost 80% of cancer we found in the world is related to lung only. We can find two different lung cancers; there are small cell lung cancer and non-small cell lung cancer. Here, we are only concentrated about the non-small cell lung cancer or (NSCLC). Here, we considered the KRAS mutation of the human gene. The KRAS biomarker is one of the main reasons for the NSCLC. Nearly 25% of the mutations happen in the form of KRAS mutation. Here, we have reviewed different deep learning and machine learning methods like convolutional neural

APA, Harvard, Vancouver, ISO, and other styles

31

Varker, Kimberly A. "Small- and non-Small- Cell Lung Cancer." Guthrie Journal 70, no. 1 (2001): 2–8. http://dx.doi.org/10.3138/guthrie.70.1.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ming, Zhang. "Effects and mechanism of anlotinib on radiosensitivity of non-small cell lung cancer cell lines a549." Journal of Medical pharmaceutical and allied sciences 12, no. 6 (2023): 6223–29. http://dx.doi.org/10.55522/jmpas.v12i6.5821.

Full text

Abstract:

To investigate the effect and mechanism of Anlotinib on radio sensitization of human lung adenocarcinoma cell line A549. Human lung adeno carcinoma cell line A549 was teated with anlotinib and/or radiotherapy, then divided four groups, control group (Ctrl), Anlotinib treatment group (A), irradiation group (RT) and Anlotinib combined with irradiation group (A+RT) . CCK8 method was used to determine cell proliferation; the clone formation experiment was used to determine the inhibitory effect on cell growth; flow cytometry was used to determine cell cycle and apoptosis; immunofluorescence of γ-H

APA, Harvard, Vancouver, ISO, and other styles

33

Deniz, Özdemir. "KAN0438757: A NOVEL PFKFB3 INHIBITOR THAT INDUCES PROGRAMMED CELL DEATH AND SUPPRESSES CELL MIGRATION IN NON-SMALL CELL LUNG CARCINOMA CELLS." Biotechnologia Acta 16, no. 5 (2023): 34–44. http://dx.doi.org/10.15407/biotech16.05.034.

Full text

Abstract:

Aim. PFKFB3 is glycolytic activators that is overexpressed in human lung cancer and plays a crucial role in multiple cellular functions including programmed cell death. Despite the many small molecules described as PFKFB3 inhibitors, some of them have shown disappointing results in vitro and in vivo. On the other hand KAN0438757, selective and potent, small molecule inhibitor has been developed. However, the effects of KAN0438757, in non-small cell lung carcinoma cells remain unknown. Herein, we sought to decipher the effect of KAN0438757 on proliferation, migration, DNA damage, and programmed

APA, Harvard, Vancouver, ISO, and other styles

34

Janho dit Hreich, Serena, Jonathan Benzaquen, Paul Hofman, and Valérie Vouret-Craviari. "The Purinergic Landscape of Non-Small Cell Lung Cancer." Cancers 14, no. 8 (2022): 1926. http://dx.doi.org/10.3390/cancers14081926.

Full text

Abstract:

Lung cancer is the most common cancer worldwide. Despite recent therapeutic advances, including targeted therapies and immune checkpoint inhibitors, the disease progresses in almost all advanced lung cancers and in up to 50% of early-stage cancers. The purpose of this review is to discuss whether purinergic checkpoints (CD39, CD73, P2RX7, and ADORs), which shape the immune response in the tumor microenvironment, may represent novel therapeutic targets to combat progression of non-small cell lung cancer by enhancing the antitumor immune response.

APA, Harvard, Vancouver, ISO, and other styles

35

Tavartkiladze, Alexandre, Revaz Turmanidze, Gaiane Simonia, et al. "Circulating Tumor Cells and cfDNA: Key Predictive Biomarkers in Non - Small Cell Lung Cancer Progression and Treatment." International Journal of Science and Research (IJSR) 12, no. 10 (2023): 1078–81. http://dx.doi.org/10.21275/sr231013031834.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Adelstein, David J., Joseph F. Tomashefski, Norman J. Snow, Terrence P. Horrigan, and John D. Hines. "Mixed Small Cell and Non-Small Cell Lung Cancer." Chest 89, no. 5 (1986): 699–704. http://dx.doi.org/10.1378/chest.89.5.699.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mangum, M. D., F. A. Greco, J. D. Hainsworth, K. R. Hande, and D. H. Johnson. "Combined small-cell and non-small-cell lung cancer." Journal of Clinical Oncology 7, no. 5 (1989): 607–12. http://dx.doi.org/10.1200/jco.1989.7.5.607.

Full text

Abstract:

Nine (2%) of 429 small-cell lung cancer (SCLC) patients seen at Vanderbilt University between 1977 and 1983 had a combined subtype SCLC at diagnosis (ie, small-cell carcinoma plus squamous cell or adenocarcinoma). Staging procedures and chemotherapy treatment were uniform for all 429 patients. The diagnosis of combined histology was established via bronchoscopy (six patients), needle aspiration biopsy (one), lymph node biopsy (one), and thoracotomy (one). The clinical characteristics of the combined subtype patients were similar to patients with other subtypes of SCLC (ie, there were no differ

APA, Harvard, Vancouver, ISO, and other styles

38

Al Khatib, Arwa Omar, Mohamed El-Tanani, and Hisham Al-Obaidi. "Inhaled Medicines for Targeting Non-Small Cell Lung Cancer." Pharmaceutics 15, no. 12 (2023): 2777. http://dx.doi.org/10.3390/pharmaceutics15122777.

Full text

Abstract:

Throughout the years, considerable progress has been made in methods for delivering drugs directly to the lungs, which offers enhanced precision in targeting specific lung regions. Currently, for treatment of lung cancer, the prevalent routes for drug administration are oral and parenteral. These methods, while effective, often come with side effects including hair loss, nausea, vomiting, susceptibility to infections, and bleeding. Direct drug delivery to the lungs presents a range of advantages. Notably, it can significantly reduce or even eliminate these side effects and provide more accurat

APA, Harvard, Vancouver, ISO, and other styles

39

Kobayashi, Kunihiko. "4) Non-small Cell Lung Cancer." Nihon Naika Gakkai Zasshi 101, Suppl (2012): 110c—111a. http://dx.doi.org/10.2169/naika.101.110c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kobayashi, Kunihiko. "3) Non-small Cell Lung Cancer." Nihon Naika Gakkai Zasshi 101, no. 9 (2012): 2520–25. http://dx.doi.org/10.2169/naika.101.2520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Yasufuku, Kazuhiro, and Shaf Keshavjee. "Staging Non–Small Cell Lung Cancer." Clinical Pulmonary Medicine 17, no. 5 (2010): 223–31. http://dx.doi.org/10.1097/cpm.0b013e3181ef721c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Rossi, Giulio, Giuseppe Pelosi, Mattia Barbareschi, Paolo Graziano, Alberto Cavazza, and Mauro Papotti. "Subtyping Non–Small Cell Lung Cancer." International Journal of Surgical Pathology 21, no. 4 (2013): 326–36. http://dx.doi.org/10.1177/1066896913489346.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Quint, Leslie Eisenbud. "Staging non-small cell lung cancer." Cancer Imaging 7, no. 1 (2007): 148–59. http://dx.doi.org/10.1102/1470-7330.2007.0026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Baron, M. Gonzalez, C. Garcia Giron, P. Zamora, et al. "Non-Small-Cell Lung Cancer (NSCLC)." American Journal of Clinical Oncology 15, no. 1 (1992): 23–28. http://dx.doi.org/10.1097/00000421-199202000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Laskin, Janessa J., Alan B. Sandler, and David H. Johnson. "Introduction: Non-Small Cell Lung Cancer." Seminars in Oncology 32, no. 3 (2005): 251–52. http://dx.doi.org/10.1053/j.seminoncol.2005.04.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

KOYAMA, RYO, and KAZUHISA TAKAHASHI. "Non-Small-Cell Lung Cancer Treatment." Juntendo Medical Journal 62, no. 1 (2016): 7–12. http://dx.doi.org/10.14789/jmj.62.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Armstrong, P., and J. M. Vincent. "Staging non-small cell lung cancer." Clinical Radiology 48, no. 1 (1993): 1–10. http://dx.doi.org/10.1016/s0009-9260(05)80099-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Palma, David A., and Gregory M. M. Videtic. "Oligometastatic Non-Small-Cell Lung Cancer." International Journal of Radiation Oncology*Biology*Physics 93, no. 2 (2015): 223–26. http://dx.doi.org/10.1016/j.ijrobp.2015.07.2277.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Heist, Rebecca S., and Jeffrey A. Engelman. "SnapShot: Non-Small Cell Lung Cancer." Cancer Cell 21, no. 3 (2012): 448–448. http://dx.doi.org/10.1016/j.ccr.2012.03.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sherry, Victoria. "Metastatic non—small cell lung cancer." Nurse Practitioner 41, no. 12 (2016): 1–5. http://dx.doi.org/10.1097/01.npr.0000502795.96478.bb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!